Top ▲
| Ligand name | ID | Synonyms | |||||||
| A | Back to top | ||||||||
| abagovomab | 8265 | ACA125, MEN-2234 | |||||||
| ABBV-154 | 12918 | ADC11 | |||||||
| ABBV-3373 |
|
12917 | ADC 122 | ||||||
| abciximab |
|
6584 | 7E3 antibody, antiGPIIBIIIa, C7E3, ReoPro® | ||||||
| abelacimab | 12417 | MAA-868, MAA868, NVS250519 | |||||||
| AbGn-168H |
|
10013 | AbGn-168, neihulizumab | ||||||
| abrezekimab |
|
9806 | CDP7766, UCB-4144, UCB4144, VR-942 | ||||||
| abrilumab |
|
11531 | AMG 181, AMG-181, MEDI-7183, MEDI7183 | ||||||
| adalimumab |
|
|
4860 | D2E7, Humira® | |||||
| aducanumab |
|
8325 | aducanumab-avwa, Aduhelm®, BART, BIIB-037, BIIB037 | ||||||
| AFM13 |
|
10067 | AFM 13, AFM-13 | ||||||
| alemtuzumab |
|
|
6770 | campath 1H, Campath®, campath-1H, Lemtrada® | |||||
| alirocumab |
|
6744 | Praluent®, REGN727, SAR-236553, SAR236553 | ||||||
| ALT-803 |
|
9615 | IL-15 N72D:IL-15RαSu/Fc, IL-15SA, N-803 | ||||||
| amatuximab | 7750 | MORAb-009 | |||||||
| AMG820 |
|
9106 | |||||||
| amivantamab |
|
10505 | amivantamab-vmjw, JNJ-61186372, JNJ-6372, JNJ61186372, Rybrevant® | ||||||
| AMY109 |
|
12789 | AMY-109, H1009/L395-F1974m | ||||||
| anatumomab mafenatox |
|
9947 | 5T4FabV13SEAD227A, ABR 214936, ABR-214936, ABR214936, pMB125, PNU 214936, PNU-214936, PNU214936, TTS-CD2 | ||||||
| andecaliximab |
|
9510 | GS-5745, GS5745 | ||||||
| anifrolumab |
|
|
8258 | anifrolumab-fnia, MDX-1333, MEDI-546, Saphnelo® | |||||
| anti-ILT7 antibody | 9124 | ||||||||
| anumigilimab | 11761 | CSL-324, CSL324 | |||||||
| apitegromab | 11180 | SRK-015, SRK015 | |||||||
| ASC06-IgG1 | 12564 | ||||||||
| atezolizumab |
|
|
7990 | MPDL3280A, Tecentriq® | |||||
| atibuclimab |
|
11326 | IC14 | ||||||
| avdoralimab |
|
11345 | anti-hC5aR-32F3A6 GL, IPH-5401, NN-8210, NNC-0215-0384 | ||||||
| avelumab |
|
|
8735 | Bavencio®, MSB-0010718C, MSB0010718C | |||||
| avizakimab | 12270 | BOS 161721, BOS161721 | |||||||
| B | Back to top | ||||||||
| bamlanivimab | 11325 | LY-3819253, LY-CoV555, LY3819253 | |||||||
| bapineuzumab | 6930 | 3D-6, AAB-001 | |||||||
| barzolvolimab | 11607 | CDX-0159 | |||||||
| basiliximab |
|
|
6879 | CHI-621, L04AC02, SDZ-CHI-621, Simulect® | |||||
| bavituximab | 8002 | Tarvacin ch3G4 | |||||||
| bebtelovimab | 11921 | LY-3853113, LY-CoV-1404, LY-CoV1404, LY3853113 | |||||||
| begelomab |
|
8691 | Begendina&rg; (proprietary name), BT 5/9, SAND 26 | ||||||
| belantamab mafodotin |
|
|
11117 | belamaf, belantamab mafodotin-blmf, Blenrep®, GSK-2857916, GSK2857916 | |||||
| belimumab |
|
|
6887 | Benlysta®, hBlySmAb-1.1, LimphoStat-B, lymphostat-B | |||||
| bemarituzumab | 11278 | FPA-144, FPA144 | |||||||
| benralizumab |
|
|
7674 | BIW-8405, Fasenra®, KHK4563, MEDI-563 | |||||
| bermekimab | 8089 | MABp1, RA-18C3, Xilonix® (proposed trade name) | |||||||
| bevacizumab |
|
6771 | Avastin®, rhuMAb-VEGF | ||||||
| bexmarilimab |
|
12907 | Clevegen, FP-1305, FP1305 | ||||||
| bifikafusp alfa |
|
9756 | Darleukin, L19-IL2, L19IL2 | ||||||
| bimagrumab | 8086 | BYM-338, BYM338 | |||||||
| bimekizumab |
|
|
9411 | bimekizumab-bkzx, Bimzelx®, CA028_0496, CDP4940, gL7gH9, UCB-4940, UCB4940, Zu-G1 | |||||
| bintrafusp alfa | 11376 | M7824, MSB0011359C | |||||||
| blinatumomab |
|
|
7384 | Blincyto®, bscCD19xCD3, MEDI-538, MT-103, MT103 | |||||
| bococizumab | 7730 | PF-04950615, RN-316, RN316 | |||||||
| BPS-804 | 9202 | BPS 804, BPS804 | |||||||
| brazikumab |
|
9293 | AMG 139, AMG-139, MEDI2070 | ||||||
| brentuximab vedotin |
|
|
6772 | Adcetris®, anti-CD30 ADC SGN-35, SGN 35 | |||||
| briakinumab |
|
9213 | ABT-874, J-695, J695, Ozespa | ||||||
| brodalumab |
|
|
7540 | AMG-827, AMG827, Kyntheum®, Lumicef®, Siliq® | |||||
| brolucizumab |
|
8713 | Beovu®, brolucizumab-dbll, ESBA-1008, ESBA1008, RTH258 | ||||||
| brontictuzumab | 11361 | OMP-52M51, OMP52M51 | |||||||
| BsAb (CD89-CD20) |
|
9833 | |||||||
| burosumab |
|
9292 | burosumab-twza, Crysvita®, KRN-23, KRN23, N5KG1_C10_LH, UX-023, UX023 | ||||||
| C | Back to top | ||||||||
| cabiralizumab |
|
9107 | BMS-986227, FPA-008, FPA008 | ||||||
| cadonilimab |
|
|
12966 | AK-104, AK104 | |||||
| calpurbatug | 13036 | TRL1068 | |||||||
| camrelizumab |
|
|
9758 | INCSHR1210, SHR-1210 | |||||
| canakinumab |
|
|
6773 | ACZ 885, ACZ885, Ilaris® | |||||
| caplacizumab |
|
9123 | ALX-0081, anti-vWF Nanobody, Cablivi®, caplacizumab-yhdp | ||||||
| capromab |
|
6878 | capromab pendetide, CYT-351, CYT-356, Indium In 111 capromab, ProstaScint® | ||||||
| carotuximab | 9098 | c-SN6j, TRC-105, TRC105 | |||||||
| casirivimab |
|
11327 | REGN-10933, Ronapreve® (imdevimab + casirivimab) | ||||||
| catumaxomab |
|
7385 | L01XC09, Removab® | ||||||
| cemiplimab |
|
|
10090 | cemiplimab-rwlc, Libtayo®, REGN-2810, REGN2810, SAR-439684, SAR439684 | |||||
| certolizumab pegol |
|
|
6774 | CDP870, Cimzia®, PHA 738144 | |||||
| cetuximab |
|
6882 | C225, Erbitux®, IMC-225, IMC-C225 | ||||||
| CFZ533 |
|
9802 | CFZ-533, iscalimab (proposed INN), NVP-CFZ533, OM11-62MF | ||||||
| cilgavimab |
|
11329 | AZD1061, COV2-2130, Evusheld® (tixagevimab + cilgavimab) | ||||||
| CIS43 |
|
11254 | |||||||
| clazakizumab |
|
9195 | ALD-518, ALD518, BMS-945429 | ||||||
| codrituzumab | 8406 | GC33, RG-7686, RG7686, RO-5137382, RO5137382 | |||||||
| concizumab |
|
11182 | Alhemo®, Anti-TFPI, mab2021, NN7415 | ||||||
| COVA322 |
|
10469 | |||||||
| CR3022 | 11076 | ||||||||
| crenezumab | 6934 | MABT-5102A, Mabt5102A | |||||||
| crizanlizumab |
|
10550 | Adakveo®, crizanlizumab-tmca, hSel001, SEG101 | ||||||
| crotedumab | 9614 | REGN-1193, REGN1193 | |||||||
| crovalimab |
|
12790 | RG-6107, RG6107, SKY59 | ||||||
| cusatuzumab |
|
9778 | ARGX-110, ARGX110, clone 41D12 | ||||||
| D | Back to top | ||||||||
| daclizumab |
|
|
6880 | L04AC01, RO-24-7375, Ro-247375, Zenapax® | |||||
| dalutrafusp alfa | 11776 | AGEN-1423, AGEN1423, GS-1423 | |||||||
| dapirolizumab pegol |
|
11123 | CDP-7657, CDP7657, DZP | ||||||
| daratumumab |
|
|
7395 | 3003-005, Darzalex®, HuMax-CD38, JNJ-54767414 | |||||
| dectrekumab |
|
8714 | QAX-576, QAX576 | ||||||
| demcizumab | 8451 | OMP-21M18, OMP21M18 | |||||||
| denosumab |
|
6886 | AMG-162, M05BX04, Prolia®, Xgeva® | ||||||
| depatuxizumab mafodotin | 7970 | ABT-414 | |||||||
| dezamizumab | 8255 | GSK-2398852, GSK2398852 | |||||||
| dinutuximab |
|
7979 | APN-311, Ch14.18, MAb-14.18, Unituxin® | ||||||
| domagrozumab | 9096 | clone OGD1.0.0, PF-06252616, PF06252616 | |||||||
| donanemab | 8357 | ||||||||
| dostarlimab |
|
|
11518 | ANB-011, dostarlimab-gxly, Jemperli®, TSR-042, WBP-285 | |||||
| dupilumab |
|
|
7574 | Dupixent®, REGN668, SAR231893 | |||||
| durvalumab |
|
|
7985 | anti-B7H1 monoclonal antibody, Imfinzi®, MEDI-4736, MEDI4736 | |||||
| dusigitumab | 7749 | MEDI-573 | |||||||
| DX-2507 |
|
9959 | |||||||
| E | Back to top | ||||||||
| eblasakimab | 11770 | ASLAN-004, ASLAN004, CSL 334, CSL-334 | |||||||
| eculizumab |
|
|
6884 | h5G1.1, h5G1.1VHC, Soliris® | |||||
| edrecolomab |
|
7984 | 17-1A, PANOREX® (proposed trade name) | ||||||
| efalizumab |
|
|
6593 | anti alphaL integrin, antiCD11 alpha, hu1124, Raptiva® | |||||
| efgartigimod alfa |
|
|
9777 | ARGX-113, efgartigimod alfa-fcab, Vyvgart® | |||||
| efmarodocokin alfa | 12212 | IL-22Fc, RG 7880, RG7880, UTTR1147A | |||||||
| eldelumab |
|
9047 | BMS-936557, MDX-1100 | ||||||
| elezanumab |
|
9290 | ABT-555, AE12-1Y-QL | ||||||
| elgemtumab | 8715 | LJM716, NVS201010 | |||||||
| elotuzumab |
|
|
8361 | BMS-901608, Empliciti®, HuLuc63 | |||||
| elranatamab |
|
|
12889 | elranatamab-bcmm, Elrexfio®, PF-06863135, PF06863135 | |||||
| emactuzumab |
|
8944 | RG7155, RO5509554 | ||||||
| emapalumab |
|
|
9295 | emapalumab-lzsg, Gamifant®, NI-0501, NI0501 | |||||
| emfizatamab | 12177 | GNC 038, GNC-038, GNC038 | |||||||
| emibetuzumab | 7748 | LA480, LY-2875358, LY2875358 | |||||||
| emicizumab |
|
9744 | ACE-910, ACE910, emicizumab-kxwh, Hemlibra®, RG6013 | ||||||
| enfortumab vedotin |
|
10738 | ASG-22CE, enfortumab vedotin-ejfv, Padcev® | ||||||
| enoblituzumab |
|
9589 | MGA-271, MGA271 | ||||||
| enokizumab |
|
8934 | 7F3com-2H2, MEDI-528, MEDI528 | ||||||
| envafolimab |
|
|
10492 | Envida®, KN-035, KN035 | |||||
| epcoritamab |
|
|
11442 | epcoritamab-bysp, Epkinly®, GEN-3013, GEN3013 | |||||
| epratuzumab |
|
8088 | 90Y-DOTA-hLL2, 90Y-epratuzumab tetraxetan, 90Y-hLL2, AMG-412, IMMU-hLL2, LymphoCide® (proposed proprietary name) | ||||||
| eptinezumab |
|
10694 | ALD-403, ALD403, eptinezumab-jjmr, Vyepti® | ||||||
| erenumab |
|
9250 | Aimovig®, AMG 334, AMG-334, erenumab-aooe | ||||||
| etaracizumab | 6596 | etaratuzumab, hLM60, MEDI-522 | |||||||
| etesevimab | 11331 | CB-6, JS-016, LY-CoV016, LY3832479 | |||||||
| etrolizumab |
|
8407 | PRO145223, RG-7413, RG7413, rhuMAb Beta7 | ||||||
| evinacumab |
|
8717 | evinacumab-dgnb, Evkeeza®, REGN1500 | ||||||
| evolocumab |
|
7343 | AMG-145, AMG145, Repatha® | ||||||
| F | Back to top | ||||||||
| factor XIIa blocking antibody 3F7 | 12771 | ||||||||
| faricimab |
|
11420 | faricimab-svoa, RG-7716, RG7716, RO-6867461, RO6867461, Vabysmo® | ||||||
| fasinumab | 8965 | REGN475, SAR164877 | |||||||
| feladilimab | 11649 | GSK-3359609 | |||||||
| fezakinumab |
|
9281 | ILV-094 | ||||||
| fibatuzumab | 8925 | KB-004, KB004 | |||||||
| fontolizumab |
|
9847 | HuZAF | ||||||
| fremanezumab |
|
9208 | Ajovy®, fremanezumab-vfrm, LBR-101, PF-04427429, PF-4427429, RI-307, RN-307, RN307, TEV-48125 | ||||||
| fresolimumab | 8264 | GC1008, PET1073G12 | |||||||
| fulranumab | 8964 | AMG-403, JNJ-42160443 | |||||||
| G | Back to top | ||||||||
| galcanezumab |
|
|
8967 | clone III, Emgality®, galcanezumab-gnlm, LY-2951742, LY2951742 | |||||
| galegenimab | 11759 | 15H6v4.D221, FHTR2163, RG-6147, RG6147, RO-7171009, RO7171009 | |||||||
| gantenerumab | 6933 | R-1450, RG-1450, Ro-4909832 | |||||||
| gemtuzumab ozogamicin |
|
|
6775 | CDP 771, CMA 676, hP67.6-calicheamicin, Mylotarg®, WAY-CMA 676 | |||||
| gevokizumab |
|
7394 | XOMA 052, XOMA-052 | ||||||
| gimsilumab |
|
9624 | MORAb-022 | ||||||
| ginisortamab | 11769 | MP5D2_CL22A3, UCB-6114 | |||||||
| girentuximab | 7987 | cG250, G250, Rencarex® (proposed proprietary name), WX-G250 | |||||||
| glembatumumab vedotin | 8926 | CDX-011, CR011-vcMMAE | |||||||
| glofitamab |
|
12758 | CD20-TCB (2:1), Columvi®, glofitamab-gxbm, RG-6026, RG6026 | ||||||
| golimumab |
|
|
6776 | CNTO-148, CNTO148, Simponi® | |||||
| GSK3050002 |
|
9623 | E6071, KANAb071 | ||||||
| guselkumab |
|
|
7998 | CNTO-1959, Tremfya® | |||||
| H | Back to top | ||||||||
| hIMB1636-MMAE | 12978 | ||||||||
| I | Back to top | ||||||||
| ianalumab |
|
10656 | VAY-736, VAY736 | ||||||
| ibalizumab |
|
|
10208 | Hu5A8, ibalizumab-uiyk, TMB-355, TMB355, TNX-355, Trogarzo® | |||||
| ibritumomab tiuxetan |
|
|
6777 | IDEC-2B8, IDEC-Y2B8-yttrium ibritumomab tiuxetan, NSC-715848, Zevalin® | |||||
| idarucizumab |
|
8298 | aDabi-Fab, BI 655075, Praxbind® | ||||||
| IGN523 | 8737 | ||||||||
| imaprelimab |
|
9805 | PRX-003, PRX003 | ||||||
| imdevimab |
|
11328 | REGN-10987, REGN10987, Ronapreve® (imdevimab + casirivimab) | ||||||
| inclacumab |
|
12312 | HuMab 002, LC1004-002, RO-4905417, RO4905417 | ||||||
| indusatumab vedotin | 8718 | 5F9vcMMAE, MLN-0264, MLN0264, TAK-264, TAK264 | |||||||
| inebilizumab |
|
7992 | HB12, inebilizumab-cdon, MEDI 551, MEDI-551, MEDI551, Uplizna® | ||||||
| infliximab |
|
|
5004 | cA2, Inflectra®, Remicade®, Remsima®, SB2, TA-650, Zymfentra® (subcutaneous formulation) | |||||
| inotuzumab ozogamicin |
|
|
8266 | Besponsa®, CMC-544 | |||||
| ipilimumab |
|
|
6888 | MDX-010, MDX-101, MDX-CTLA-4, Yervoy® | |||||
| isatuximab |
|
8719 | ch38SB19, hu38SB19, isatuximab-irfc, SAR-650984, SAR650984, Sarclisa® | ||||||
| istiratumab | 8930 | MM-141, MM141 | |||||||
| itolizumab |
|
|
9421 | Alzumab®, T1h | |||||
| ixekizumab |
|
|
7541 | LY-2439821, LY2439821, Taltz® | |||||
| L | Back to top | ||||||||
| labetuzumab | 8251 | CEACIDE®, hMN14 | |||||||
| labetuzumab govitecan | 8252 | hMN-14-SN-38, hMN-14-SN-38 ADC, IMMU 130, IMMU-130 | |||||||
| lampalizumab | 8294 | anti-factor D, FCFD4514S, RG7417 | |||||||
| lanadelumab |
|
9094 | DX-2930, lanadelumab-flyo, Takhzyro®, X124-G01 | ||||||
| landogrozumab | 8730 | LY-2495655, LY2495655 | |||||||
| lebrikizumab |
|
7684 | MILR1444A, RG3637, TNX-650 | ||||||
| lecanemab |
|
12202 | BAN-2401, BAN2401, lecanemab-irmb, Leqembi® | ||||||
| lenzilumab |
|
8935 | KB-003, KB003 | ||||||
| lepunafusp alfa | 11773 | JR-171, JR171 | |||||||
| leronlimab |
|
10752 | PRO 140, PRO-140, PRO140, Vyrologix® | ||||||
| lifastuzumab vedotin | 8405 | DNIB0600A, RG-7599, RG7599 | |||||||
| ligelizumab |
|
8997 | CL-2C, NVP-QGE031, QGE031 | ||||||
| lilotomab |
|
9950 | Betalutin®, HH1, tetulomab | ||||||
| lintuzumab |
|
7983 | ACTIMAB®, HuM195, SGN-33, SMART M195 | ||||||
| lirilumab |
|
9310 | 1-7F9, BMS-986015, IPH2102 | ||||||
| litifilimab |
|
11122 | BIIB-059, BIIB059 | ||||||
| livmoniplimab | 11762 | 39B6-AYE, ABBV-151, ARGX-115, ARGX115, MHG-8, MHGARP-8, PR-1762844 | |||||||
| loncastuximab tesirine |
|
11521 | ADCT-402, ADCT402, loncastuximab tesirine-lpyl, RB4v1.2-SG-3249, Zynlonta® | ||||||
| lorvotuzumab mertansine | 7431 | BB-10901, IMGN901 | |||||||
| lulizumab pegol |
|
8460 | BMS-931699, BMS931699 | ||||||
| lutikizumab |
|
9297 | ABT-981, E26.13-SS-X3 | ||||||
| LY2928057 | 8416 | ||||||||
| LY3022855 |
|
9109 | IMC-CS4 | ||||||
| M | Back to top | ||||||||
| MAB92 |
|
9665 | |||||||
| mAb 4A8 | 11079 | ||||||||
| magrolimab |
|
12652 | Hu5F9-G4 | ||||||
| margetuximab |
|
8686 | Margenza®, margetuximab-cmkb, MGAH-22 | ||||||
| masavibart | 12322 | ZRC3308-A7 | |||||||
| mavrilimumab |
|
7785 | CAM-3001, KPL-301 | ||||||
| MCS110 |
|
9110 | |||||||
| meplazumab |
|
11026 | HP6H8, Ketantin® | ||||||
| mepolizumab |
|
|
7685 | Nucala®, SB-240563 | |||||
| mezagitamab |
|
10609 | TAK-079, TAK079 | ||||||
| milatuzumab |
|
8267 | hLL1, IMMU-115 | ||||||
| mirikizumab |
|
|
9846 | Antibody I [US9023358], LY-3074828, LY3074828, mirikizumab-mrkz, Omvoh® | |||||
| mirvetuximab soravtansine |
|
12250 | Elahere®, IMGN-853, IMGN853, M9346A-sulfo-SPDB-DM4, mirvetuximab soravtansine-gynx | ||||||
| mitumomab | 7981 | monoclonal antibody BEC2 | |||||||
| MM-111 | 8931 | ||||||||
| MM-151 | 9125 | ||||||||
| mogamulizumab |
|
|
6477 | KW-0761, mogamulizumab-kpkc, Poteligeo® | |||||
| monalizumab |
|
8323 | humZ270, IPH-2201, NN8765-3658 | ||||||
| mosunetuzumab |
|
12298 | BTCT4465A, CD20-TDB, Lunsumio®, mosunetuzumab-axgb, RG-7828, RO7030816 | ||||||
| moxetumomab pasudotox |
|
|
7675 | CAT-8015, GCR-8015, HA22, Lumoxiti®, moxetumomab pasudotox-tdfk | |||||
| mupadolimab | 11758 | CPI-006, CPI006, CPX-006, CPX006 | |||||||
| muromonab-CD3 |
|
|
6889 | L04AA02, OKT-3, Orthoclone Okt3® | |||||
| N | Back to top | ||||||||
| namilumab |
|
10370 | AMG203, MT203 | ||||||
| naptumomab estafenatox |
|
9948 | ABR-217620, ABR217620, Anyara (proposed trade name), TTS CD3, TTS-CD3 | ||||||
| naratuximab emtansine |
|
9949 | IMGN-529, IMGN529, K7153A-SMCC-DM1 | ||||||
| natalizumab |
|
|
6591 | AN100226, anti-alpha4 integrin, anti-VLA4, Tysabri® | |||||
| naxitamab |
|
11341 | DANYELZA®, hu3F8, naxitamab-gqgk | ||||||
| necitumumab |
|
8090 | 11F8, IMC-11F8, LY3012211, Portrazza® | ||||||
| nemolizumab |
|
|
8720 | CD14152, CIM 331, CIM331, Mitchga® | |||||
| nesvacumab | 8457 | REGN-910, REGN910, SAR307746 | |||||||
| nimotuzumab |
|
7988 | h-R3, THERACIM®, Theraloc® | ||||||
| nivolumab |
|
|
7335 | BMS-936558, MDX-1106, ONO-4538, Opdivo® | |||||
| NP137 | 12848 | ||||||||
| nurulimab |
|
12992 | BCD-145, BCD145 | ||||||
| O | Back to top | ||||||||
| obinutuzumab |
|
|
6941 | GA-101, GA101, Gazyva® | |||||
| obrindatamab | 12586 | (formerly orlotamab), MGD-009, MGD009 | |||||||
| ocrelizumab |
|
|
7580 | 2H7, Ocrevus®, PRO70769, RG1594 | |||||
| odronextamab | 12690 | REGN-1979, REGN1979 | |||||||
| ofatumumab |
|
|
6778 | Arzerra®, GSK 1841157, GSK1841157, humax-CD20, Kesimpta® (subcutaneous), OMB-157, OMB157 | |||||
| olaratumab |
|
9172 | IMC-3G3, Lartruvo®, LY3012207 | ||||||
| oleclumab |
|
9596 | MEDI 9447, MEDI-9447 | ||||||
| olokizumab | 11601 | CDP 6038, CDP-6038, CDP6038 | |||||||
| omalizumab |
|
|
6890 | IGE25, olizumab, R03DX05, RG-3648, rhumab-E25, Xolair® | |||||
| onartuzumab | 8966 | MetMAb, OA-5D5, OA5D5, PRO 143966 | |||||||
| onfekafusp alfa |
|
9757 | Fibromun | ||||||
| ontamalimab |
|
9340 | PF-00547659, PF-547659, SHP647 | ||||||
| opicinumab | 8923 | BIIB-033, BIIB033 | |||||||
| OSE-127 |
|
9604 | Effi-7 | ||||||
| osocimab | 11366 | BAY 1213790, BAY-1213790, BAY1213790 | |||||||
| otelixizumab | 8458 | ChAglyCD3, TRX4 | |||||||
| otilimab | |||||||||